Treatment with BDC-1001 at the recommended Phase 2 dose resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with. | May 25, 2023
Bolt Biotherapeutics (BOLT) Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Bolt Biotherapeutics (BOLT) Reports Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with. | March 29, 2023
Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safetyBDC-1001 advances. | March 29, 2023